ABDX – Abingdon Health Plc

Shares in Abingdon Health (LSE:ABDX), the York-based lateral flow diagnostics group, moved into focus at the end of July after the company told investors that unaudited revenue for the year to 30 June 2026 had climbed 31% to around £11.3m, and, more significantly for a business that has never turned a full-year profit, that it had reached adjusted EBITDA profitability in the second half of the financial year.

The trading update, released on 29 July 2026, matters because it marks the point at which Abingdon's long-running pivot from a pandemic-era antibody-test supplier into a contract development and manufacturing organisation (CDMO) for rapid tests began to show through in the numbers. Management framed the second-half result as evidence that the operating model can cover its costs once revenue reaches sufficient scale, though full audited results are not due until early October 2026.

Company background

Founded in 2008 by Dr Chris Hand and Chris Yates, Abingdon Health (LSE:ABDX) develops and manufactures lateral flow tests, the same immunoassay format familiar from home Covid kits and pregnancy tests. It works both as a manufacturer for third-party clients and as a developer of its own branded products, spanning infectious disease, sexual health, fertility, animal health and plant pathology.

The company came to wider attention during the pandemic with its AbC-19 rapid antibody test, developed as part of a UK consortium, and floated on London's AIM market in December 2020. Since then it has repositioned around a CDMO services model, adding regulatory capability through the 2024 acquisition of CS Lifesciences, an analytical laboratory in Doncaster, and, from April 2025, a full-service development and manufacturing site in Madison, Wisconsin, giving customers the option to develop and manufacture on either side of the Atlantic.

The announcement

The July update was a trading statement rather than audited results, so the figures should be read as provisional. Abingdon reported that revenue for FY26 was expected to be approximately £11.3m, up from £8.6m in FY25, with the second half delivering roughly 63% more revenue than the first. That skew reflects the timing of contract development work rather than a one-off.

The headline profitability claim is narrower than it first appears. Abingdon said it had moved into adjusted EBITDA profitability in the second half, not across the full year. The company defines adjusted EBITDA as operating profit or loss before depreciation, amortisation, share-based payment charges and non-recurring items. Executive chairman Dr Chris Hand said the group was 'delighted to announce revenue growth of over 30% and a move into adjusted EBITDA profitability in the second half of the year.'

Key financial figures

Alongside the revenue and profitability signals, Abingdon reported cash of £2.9m at 30 June 2026, up from £1.9m a year earlier, a position helped by a placing and retail offer that raised about £3.2m net in October 2025. The company also flagged that roughly £0.5m of reader-unit sales originally expected in the second half had slipped into August at a customer's request, a reminder that revenue in this business can be lumpy and timing-sensitive.

Contract Development, or R&D, revenues were identified as the main driver of the strong second-half performance, reflecting the multiple CDMO contracts announced during the prior financial year now moving into active work.

Comparison with earlier periods

The trajectory is one of steady top-line growth off a low base. Revenue rose from £6.1m in FY24 to £8.6m in FY25, a 40% increase, and is now guided to about £11.3m for FY26. On profitability, the direction of travel is clearer than the absolute position: FY25 carried an adjusted EBITDA loss of £2.7m, with the second half of that year already narrowing to a £0.7m loss against a £1.9m first-half loss.

On our reading, the FY26 second-half result therefore represents a continuation of that improving half-on-half pattern rather than a sudden break. A full-year adjusted EBITDA figure for FY26 was not disclosed in the update, and the first-half loss means the group has not yet demonstrated sustained profitability across a complete year.

Strategy and growth drivers

Abingdon's strategy rests on winning and executing CDMO contracts, where it is paid to develop and then manufacture bespoke lateral flow tests for pharmaceutical, veterinary and diagnostics customers. The prior year saw a run of wins, including a US$2m sexually transmitted disease test contract, a €2m companion diagnostic programme, a US$2.5m companion diagnostic development contract and a CAD$2m multiplex test system.

The US build-out is central to the plan. Its Madison site had five contract development projects underway by October 2025, spanning pharmaceutical, veterinary and infectious disease applications, and the company has begun a second phase of expansion to install high-throughput manufacturing equipment mirroring its UK lines. Management argues this dual-geography capability is attractive to customers wary of supply-chain disruption, and the board said it was confident of further growth in FY27 on the strength of programmes already underway.

Industry and competitive context

The lateral flow CDMO market sits at the intersection of a maturing rapid-test industry and rising demand for decentralised and point-of-care diagnostics. Demand has normalised sharply since the Covid boom, which hurt many pandemic-era test makers, and Abingdon's shift towards outsourced development and manufacturing is in part an attempt to build a more durable, recurring revenue base than one-off product sales allowed.

It competes against larger, better-capitalised contract manufacturers and against customers' in-house capabilities. Its differentiation rests on end-to-end service, from assay development through regulatory support to manufacturing, and on offering both UK and US production. Scale, however, remains modest relative to global diagnostics peers.

Key risks and uncertainties

Several caveats temper the optimism. The profitability milestone applies only to the second half, and the reported figures are unaudited pending October's results. Revenue remains project-based and can shift between periods, as the £0.5m deferral into August illustrates, making any single half-year an imperfect guide.

Cash of £2.9m provides limited headroom for a company still investing in US expansion, and Abingdon has returned to the market for equity more than once, in August 2024 and October 2025, raising the prospect of further dilution if internal cash generation does not build as hoped. Revenue also still includes an element of grant-funded income, and the CDMO order book depends on continued contract wins in a competitive market where customer decisions and regulatory timelines lie largely outside the company's control.

Milestones to watch

The next hard data point is the full audited results for the year to 30 June 2026, expected in early October, which should confirm the revenue figure, reveal the full-year adjusted EBITDA outcome and clarify the operating loss. Investors will also be watching for the delayed reader-unit revenue to land in the first quarter of FY27, for updates on the Madison expansion and new CDMO contract announcements, and for any concrete guidance on the pace of FY27 growth.

Conclusion

Abingdon Health's update points to genuine operational progress: a third consecutive year of double-digit revenue growth and, for the first time, a half-year in which the underlying business covered its cash costs. For a company that has spent years rebuilding after the collapse of pandemic demand, that is a meaningful marker.

The qualifications are equally clear. The profitability is second-half and adjusted, the numbers are unaudited, cash is thin and revenue timing is volatile. On our reading, the October results will be the real test of whether the second half was a turning point or simply the strongest phase of an inherently uneven year. For now, the direction of travel is encouraging without yet settling the question of durable, full-year profitability.